Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart Failure
Why the study?
Does the selective ETA receptor antagonist darusentan improve hemodynamic parameters in patients with chronic heart failure?
Population
157 patients with chronic heart failure, pulmonary capillary wedge pressure ≥12 mm Hg, and a cardiac index…
Comparison
Darusentan orally in addition to standard… vs Matching placebo in addition to standard therapy
Design
RCT, randomly assigned, double-blind
Follow-up
3 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports short-term darusentan use for hemodynamic optimization in chronic HF; extends RCT evidence for selective ETA antagonism.
Structured PICO
Does the selective ETA receptor antagonist darusentan improve hemodynamic parameters in patients with chronic heart failure?
P
Population
157 patients with chronic heart failure (present or recent NYHA class III of at least 3 months duration), pulmonary capillary wedge pressure ≥12 mm Hg, and a cardiac index ≤2.6 L/min/m²
I
Intervention
Darusentan (30, 100, or 300 mg/d) orally in addition to standard therapy for 3 weeks
C
Comparator
Matching placebo in addition to standard therapy
O
Outcome
Hemodynamic and neurohumoral effects, specifically change in cardiac index after 3 weeks of treatmentsurrogate
Short-term selective ETA receptor blockade with darusentan improves cardiac index and systemic vascular resistance in patients with chronic heart failure, though higher doses may increase adverse events.
Limitations
- Short-term study duration (3 weeks)
Cite This Study
Lüscher et al. (2002) studied this question.